[en] iron oxide nanoparticles; [en] magnetic resonance imaging; [en] apoptosis; [en] Phage display
Abstract :
[en] Phage display, an extremely promising technology in the context of molecular imaging, allows for the selection of peptides interacting with virtually any target from a heterogeneous mixture of bacteriophages. In this work, we propose the concept of magnetophages, obtained by covalent coupling of ultrasmall particles of iron oxide (USPIO) to the proteins of the phage wall. To validate magnetophages as a magnetic resonance imaging contrast agent (MRI), we have used as a prototype the clone E3 because of its specific affinity for phosphatidylserine, a marker of apoptosis. Enzyme-linked immunosorbent assay showed that E3 magnetophages incubated with phosphatidylserine retained the properties of the nonmagnetically labeled phages. The usefulness of magnetophages as an MRI contrast agent was estimated by incubation with phosphatidylcholine and phosphatidylserine or with apoptotic and control cells. Under these conditions, E3 magnetophages allow the discrimination of phosphatidylserine from phosphatidylcholine and of apoptotic cells from control ones. Injected in vivo, magnetophages are rapidly cleared from the blood stream and internalized by the phagocytic cells of the liver. To abrogate this problem, USPIO were pegylated to obtain stealthy E3-PEG-magnetophages, invisible to phagocytic cells, which were successfully targeted to apoptotic liver. If this feature demonstrated for E3 magnetophages can be extrapolated to other phage display selected entities, magnetophages become an original system which allows validation of the candidate binding peptides before their synthesis is considered. The concept of the magnetophage could be extended to other imaging modalities by replacing USPIO with an adequate reporter (i.e., radiolabeled phages).
Disciplines :
Radiology, nuclear medicine & imaging Biotechnology Chemistry
Weissleder, R. (1999) Molecular imaging: exploring the next frontier. Radiology 212, 609-614.
Smith, G. P., and Petrenko, V. A. (1997) Phage display. Chem. Rev. 97, 391-410.
Scott, J. K., and Smith, G. P. (1990) Searching for peptide ligands with an epitope library. Science 249, 386-390.
Burritt, J. B., Bond, C. W., Doss, K. W., and Jesaitis, A. J. (1996) Filamentous phage display of oligopeptide libraries. Anal. Biochem. 238, 1-13.
Zwick, M. B., Shen, J., and Scott, J. K. (1998) Phage-displayed peptide libraries. Curr. Opin. Biotechnol. 9, 427-436.
Sidhu, S. S., Lowman, H. B., Cunningham, B. C., and Wells, J. A. (2000) Phage display for selection of novel binding peptides. Methods Enzymol. 328, 333-363.
Cortese, R., Monaci, P., Luzzago, A., Santini, C., Bartoli, F., Cortese, I., Fortugno, P., Galfre, G., Nicosia, A., and Felici, F. (1996) Selection of biologically active peptides by phage display of random peptide libraries. Curr. Opin. Biotechnol. 7, 616-621.
Rodi, D. J., and Makowski, L. (1999) Phage-display technology - finding a needle in a vast molecular haystack. Curr. Opin. Biotechnol. 10, 87-93.
Laumonier, C., Segers, J., Laurent, S., Michel, A., Coppée, F., Belayew, A., Vander Elst, L., and Muller, R. N. (2006) A new peptidic vector for molecular imaging of apoptosis, identified by phage display technology. J Biomol. Screen. 11, 537-545.
Weinmann, H-J., Ebert, W., Misselwitz, B., and Smitt-Willich, H. (2003) Tissue-specific MR contrast agents. Eur. J. Radiol. 46, 33-44.
Pouliquen, D., Le Jeune, J. J., Perdrisot, R., Ermias, A., and Jallet, P. (1991) Iron oxide nanoparticles for use as MRI contrast agent : pharmacokinetics and metabolism. Magn. Reson. Imaging 9, 275-283.
Van den Eijnde, S. M., Boshart, L., Reutelingsperger, C. P., De Zeeuw, C. I., and Vermeij-Keers, C. (1997) Phosphatidylserine plasma membrane asymetry in vivo : a pancellular phenomenon which alters during apoptosis. Cell Death Differ. 4, 311-316.
Schlegel, R. A., and Williamson, P. (2001) Phosphatidylserine, a death knell. Cell Death Differ. 8, 551-563.
. Josephson, L., Tung, CH., Moore, A., and Weissleder, R. (1999) High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjugate Chem. 10, 186-91.
Van Engeland, M., Nieland, L. J., Ramaekers, F. C., Schutte, B., and Reutelingsperger, C. P. (1998) Annexin V affinity assay : a review on a apoptosis detection system based on phosphatidylserine exposure. Cytometry 31, 1-9.
Burtea, C., Laurent, S., Roch, A., Vander Elst, L., and Muller, R. N. (2005) C-MALISA (cellular magnetic-linked immunosorbent assay), a new application of cellular ELISA for MRI. J. Inorg. Biochem. 99, 1135-44.
Johnson, N., Tony, T. C., and Parkin, J. M. (1997) Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis. Leuk. Res. 21, 961-972.
Walker, K. W., Llull, R., Balkian, G. K., Ko, H. S., Flores, K. M., Ramsamooj, R., Black, K. S., Hewitt, C. W., and Martin, D. C. (1992) A rapid and sensitive cellular enzyme-linked immunoabsorbent assay (CELISA) for the detection and quantitation of antibodies against cell surface determinants. A comparison of cell fixation and storage techniques. J. Immunol. Methods 154, 121-30.
Ogasawara, J., Watanabe-Fukunaga, R., Adachl, M., Matsuzawa, A., and Kasugal, T. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809.
Muller, R. N., Vander Elst, L., Rinck, P. A., Vallet, P., Maton, F., Fischer, H., Roch, A., and Van Haverbeke, Y. (1988) The importance of nuclear magnetic relaxation dispersion (NMRD) profiles in MRI contrast media development. Invest. Radiol. 23, S229-31.
Roch, A., Moiny, F., Gillis, P., and Muller, R. N. (2002) Water magnetic relaxation in superparamagnetic colloid suspensions : the effect of agglomeration. NATO Sci. Ser. II 76, 383-391.
Oswald, P., Clement, O., Chambon, C., Schouman-Claeys, E., and Frija, G. (1997) Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn. Reson. Imaging 15, 1025-1031.
Merril, C. R., Biswas, B., Carlton, R., Jensen, N. C., Creed, G. J., Zullo, S., and Adhya, S. (1996) Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U.S.A. 93, 3188-3192.
Van Beers, B., Sempoux, C., Materne, R., Delos, M., and Smith, A. M. (2001) Biodistribution of ultrasmall iron oxide particles in the rat liver. J. Magn. Reson. Imaging 13, 594-599.
Moore, A. R., Weisleder, R., and Bogdanov, A. (1997) Uptake of dextran-coated monocrystalline iron oxides in tumour cells and macrophages. J. Magn. Reson. Imaging 7, 1140-1145.
Monfardini, C., and Veronese, F. M. (1998) Stabilization of substances in circulation. Bioconjugate Chem. 9, 418-450.
Moghimi, S., and Hunter, C. (2001) Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carr. Syst. 8, 527-550.
Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M., Nishimura, H., and Matsushima, A. (1995) Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 13, 86-91.
Moghimi, S. M. (2002) Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta 1590, 131-139.
Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318.
Bhadra, D., Bhadra, S., Jain, P., and Jain, N. K. (2002) Pegnology: a review of PEG-ylated systems. Pharmazie 57, 5-29.
Li, Y., Pei, Y., Zhang, X., Gu, Z., Zhou, Z., Yuan, W., Zhou, J., Zhu, J., and Gao, X. (2001) PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Controlled Release 71, 203-211.
Zalipsky, S., Brandeis, E., Newman, M. S., and Woodle, M. C. (1994) Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 353, 71-74.
Zhang, Y., Kohler, N., and Zhang, M. (2002) Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23, 1553-1561.